Compare Hyatt Hotels Corporation (H) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Incyte Corporation — how do they compare? Hyatt Hotels Corporation trades at $161.78 (market cap $15.02B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Incyte Corporation for 33 Days on average.
| H | INCY | |
|---|---|---|
Market Cap | $15.02B | $22.85B |
Volume | 842,340 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $129.93 |
52-Week Low | $135.42 | $83.80 |
Typical Hold Time | 148 Days | 33 Days |
Enterprise Value | $18.93B | $18.35B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $161.75, up 2.93% with recent earnings beats driving momentum. The stock shows neutral technical signals with mixed moving averages and oscillators. Fundamentally, revenue grew to $7.1B in 2025 but net income turned negative at -$52M, while valuation metrics remain elevated with P/E at 196.83. Recent developments include strategic partnerships with Delta Air Lines and expansion of the Essentials portfolio.
Outlook remains cautiously optimistic with analyst consensus target of $197.77 (22% upside) but high valuation and negative cash flow trends pose risks. The company's growth initiatives and brand expansion provide opportunities, though investors should monitor debt levels and profitability recovery.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
